P1225 The interplay of donor-derived gut microbiota correlates with the efficacy of combination therapy of fecal microbiota transplantation with antibiotics for ulcerative colitis

D Ishikawa,K Nomura,X Zhang,M Kouma,T Maruyama,T Shibuya,H Watanabe,T Yamada,A Nagahara

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1355

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Our previous reports suggest fecal microbiota transplantation (FMT) following bowel cleansing with amoxicillin, fosfomycin, and metronidazole (Antibiotic FMT: A-FMT) improved its efficacy and the recovery of the Bacteroidota species composition, which is associated with ulcerative colitis (UC) severity. Building upon these previous findings, we considered that manipulating the intestinal microbiome to improve the intestinal immune system seems to be a feasible therapeutic regimen for patients with UC. In this study, we explored the gut microbiota signatures through elucidating donor-derived microbe that colonized the recipients and examined the contributions of these microbe to the efficacy of A-FMT. Methods In this study, 97 patients with active UC were enrolled between March 2014 and October 2019, of whom 49 patients were individually assigned a different donor on a one patient-to-one donor basis. FMT was performed via colonoscopy after a two-weeks oral administration of three antibacterial agents. The Lichtiger’s clinical activity index (CAI) at 4 weeks after A-FMT treatment was defined as "response" if the CAI was ≤9 points and improved by ≥3 points. Each case contributed three fecal samples (pre A-FMT, post A-FMT, and Donor). 16S rRNA gene sequence analysis was performed on 147 collected fecal samples, and 6,501 Amplicon Sequence Variants (ASV) were identified and characterized. Results In responders, the relative abundance of 6 taxonomies including Alistipes were significantly abundant in both post A-FMT treatment samples and their donors’ samples, while 6 other taxonomies were significantly low. In non-responder, significantly low proportion of donor-derived and significantly high proportions of patients-origin and/or new ASV were observed compared with responders. The similarity of gut microbiota composition between donor and post A-FMT treatment was predominantly higher in responders compared to non-responders (Figure 1). Conclusion This study revealed that the engraftment of specific donor-derived microbes is a major factor in A-FMT outcomes, which may be the foundation for precision FMT. Rational identification of patient and donor characteristics can further advance the development of A-FMT therapy for UC.

gastroenterology & hepatology

What problem does this paper attempt to address?

This paper aims to explore the relationship between the effectiveness of fecal microbiota transplantation (FMT) combined with antibiotic treatment for ulcerative colitis (UC) and the gut microbiota from donors. Specifically, researchers hope to identify which specific donor - derived microbes play a key role in the treatment and how the presence of these microbes affects the treatment outcome by analyzing the changes in the gut microbiota composition of treated patients.

### Research Background
Previous studies have shown that FMT (i.e., Antibiotic FMT, A - FMT) after intestinal cleansing with amoxicillin, fosfomycin, and metronidazole can improve the treatment effect and help restore the composition of Bacteroidota species related to the severity of UC. Based on these findings, researchers believe that improving the gut immune system by modulating the gut microbiome may be an effective treatment option for UC.

### Research Methods
- **Patient Selection**: A total of 97 patients with active - stage UC were included in the study, and 49 of them were each matched with a different donor.
- **Treatment Method**: After taking three antibacterial drugs orally for two weeks, patients underwent FMT via colonoscopy.
- **Evaluation Criteria**: Four weeks after treatment, the treatment response was evaluated according to the Lichtiger Clinical Activity Index (CAI), defined as CAI ≤ 9 points and an improvement of ≥ 3 points.
- **Sample Collection and Analysis**: Three fecal samples (before treatment, after treatment, and donor samples) were provided for each case, and 16S rRNA gene sequence analysis was performed on 167 collected fecal samples, identifying 6,501 Amplicon Sequence Variants (ASV).

### Research Results
- **Responders**: Among responders, the relative abundances of six taxa, including Alistipes, were significantly higher in post - treatment samples and their donor samples, while the other six taxa were significantly lower.
- **Non - responders**: In non - responders, the proportion of donor - derived microbes was significantly lower, while the proportion of patient - self - derived or newly emerging ASV was significantly higher.
- **Microbial Composition Similarity**: Among responders, the similarity of gut microbial composition between post - treatment samples and donor samples was significantly higher than that in non - responders.

### Conclusion
The research results indicate that the successful colonization of specific donor - derived microbes is a key factor in the treatment effect of A - FMT, which may be the basis for achieving precise FMT. Reasonably identifying the characteristics of patients and donors will further promote the development of A - FMT therapy for the treatment of UC.